Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Enhanced Cancer Immunotherapy Using microRNA-155

Posted May 09 2013 8:00pm

Description of Invention:
Tumor immunotherapy is a promising approach for the treatment of cancer. However, current T cell-based immunotherapies are limited by the poor engraftment and functionality of the transferred T cells. Moreover, lymphodepleting regimens used to enhance engraftment and function of transferred tumor-reactive T cells are plagued by life-threatening side effects.

The scientists at the NIH recently discovered that the overexpression of microRNA-155 (miR-155) in tumor-reactive murine CD8+ T cells can enhance T cell proliferation and anti-tumor efficacy without lymphodepletion and exogenous cytokine administration. Consequently, using the miR155 overexpressing human CD8+ T cells could provide a safer, more effective T cell-based immunotherapy. This invention describes miR155 CD8+ T cell compositions and methods of using the miR155 CD8+ T cells to treat cancer through adoptive immunotherapy.

Applications:
Use in enhanced adoptive immunotherapy to treat cancer

Advantages:
  • T cells with enhanced proliferation, survival, and function
  • Robust tumor response without the need of lymphodepletion and exogenous cytokine support


Development Status:
  • Pre-clinical
  • In vitro data available
  • In vivo data available (animal)


Inventors:
Yun Ji (NCI)
Nicholas P Restifo (NCI)
Luca Gattinoni (NCI)


Patent Status:
HHS, Reference No. E-272-2012/0
US, Application No. 61/716,653 filed 22 Oct 2012


Relevant Publication:
  1. Dudda JC, et al. [ PMID 23601686 ]


Collaborative Research Opportunity:
The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize the use of microRNA-155 to enhance T cell-based immunotherapies. For collaboration opportunities, please contact Luca Gattinoni at gattinol@mail.nih.gov or 301-451-6914, or Nicholas Restifo at restifo@nih.gov or 301-496-4904.


For Licensing Information Please Contact:
Whitney Hastings
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: hastingw@mail.nih.gov
Phone: 301-451-7337
Fax: 301-402-0220


Ref No: 2563

Updated: 05/2013

Post a comment
Write a comment:

Related Searches